Connexin-26 is a key factor mediating gemcitabine bystander effect

Molecular Cancer Therapeutics

Volumn 10, Issue 3, 2011, Pages 505-517

  Garcia Rodríguez, Laura ^a,b   Pérez Torras, Sandra ^c,d   Carrió, Meritxell ^a   Cascante, Anna ^a   García Ribas, Ignacio ^e   Mazo, Adela ^c   Fillat, Cristina ^a,b  

^a CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e ELI LILLY AND COMPANY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CONNEXIN 26; CONNEXIN 32; CONNEXIN 36; CONNEXIN 43; GEMCITABINE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CELL COMMUNICATION; CELL HETEROGENEITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; GAP JUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOUSE; NONHUMAN; PANCREAS BIOPSY; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR BIOPSY; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; BYSTANDER EFFECT; CELL COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; CONNEXIN 43; CONNEXINS; DEOXYCYTIDINE; GAP JUNCTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; PANCREATIC NEOPLASMS; PHOSPHORYLATION; RNA, MESSENGER;

EID: 79955751723     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0693     Document Type: Article

References (37)

1. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [see comments]. J Clin Oncol 1997;15:2403-13. (Pubitemid 27251144)
2. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007;14:3629-37. (Pubitemid 350160137)
3. Sultana A, Ghaneh P, Cunningham D, Starling N, Neoptolemos JP, Smith CT. Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer 2008;8:192.
4. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024-31.
5. Tomicic MT, Thust R, Kaina B. Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Oncogene 2002;21:2141-53. (Pubitemid 34311368)
6. Fillat C, Carrio M,Cascante A,Sangro B. Suicide gene therapy-mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther 2003;3:13-26.
7. Carrio M, Mazo A, Lopez-Iglesias C, Estivill X, Fillat C. Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells results in variable efficiency on the bystander killing: implications for gene therapy. Int J Cancer 2001;94:81-8. (Pubitemid 32801756)
8. Jimenez T, Fox WP, Naus CC, Galipeau J, Belliveau DJ. Connexin over-expression differentially suppresses glioma growth and contributes to the bystander effect following HSV-thymidine kinase gene therapy. Cell Commun Adhes 2006;13:79-92.
9. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci U S A 1996;93:1831-5. (Pubitemid 26079840)
10. Cottin S, Ghani K, de Campos-Lima PO, Caruso M. Gemcitabine intercellular diffusion mediated by gap junctions: new implications for cancer therapy. Mol Cancer;9:141.
11. Kumar NM, Gilula NB. The gap junction communication channel. Cell 1996;84:381-8. (Pubitemid 26060720)
12. Ezumi K, Yamamoto H, Murata K, Higashiyama M, Damdinsuren B, Nakamura Y, et al. Aberrant expression of connexin 26 is associated with lung metastasis of colorectal cancer. Clin Cancer Res 2008;14:677-84. (Pubitemid 351231147)
13. Mennecier G, Derangeon M, Coronas V, Herve JC, Mesnil M. Aberrant expression and localization of connexin43 and connexin30 in a rat glioma cell line. Mol Carcinog 2008;47:391-401. (Pubitemid 351614579)
14. Mesnil M, Crespin S, Avanzo JL, Zaidan-Dagli ML. Defective gap junctional intercellular communication in the carcinogenic process. Biochim Biophys Acta 2005;1719:125-45. (Pubitemid 41785641)
15. Kyo N, Yamamoto H, Takeda Y, Ezumi K, Ngan CY, Terayama M, et al. Overexpression of connexin 26 in carcinoma of the pancreas. Oncol Rep 2008;19:627-31. (Pubitemid 351330427)
16. Huch M, Abate-Daga D, Roig JM, González JR, Fabregat J, Sosnowski B, et al. Targeting the CYP2B 1/cyclophosphamide suicide system to fibroblast growth factor receptors results in a potent antitumoral response in pancreatic cancer models. Hum Gene Ther 2006;17:1187-200. (Pubitemid 44975136)
17. Liu N, Furukawa T, Kobari M, Tsao MS. Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. Am J Pathol 1998;153:263-9. (Pubitemid 28317529)
18. Villanueva A, Garcia C, Paules AB, Vicente M, Megías M, Reyes G, et al. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene 1998;17:1969-78. (Pubitemid 28488465)
19. Kapoor P, Saunders MM, Li Z, Zhou Z, Sheaffer N, Kunze EL, et al. Breast cancer metastatic potential: correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells. Int J Cancer 2004;111:693-7. (Pubitemid 39062890)
20. Heitjan DF, Manni A, Santen RJ. Statistical analysis of in vivo tumor growth experiments. Cancer Res 1993;53:6042-50. (Pubitemid 24006181)
21. Serre-Beinier V, Mas C, Calabrese A, Caton D, Bauquis J, Caille D, et al. Connexins and secretion. Biol Cell 2002;94:477-92. (Pubitemid 36113698)
22. Cascallo M, Calbo J, Capella G, Fillat C, Pastor-Anglada M, Mazo A. Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors. Oncology 2005;68:179-89. (Pubitemid 41158974)
23. El Maalouf G, Le Tourneau C, Batty GN, Faivre S, Raymond E. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat Rev 2008.
24. Pérez-Torras S, García-Manteiga J, Mercadé E, Casado FJ, Carbó N, Pastor-Anglada M, et al. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. Biochem Pharmacol 2008;76:322-9.
25. Gamblin TC, Egorin MJ, Zuhowski EG, Lagattuta TF, Herscher LL, Russo A, et al. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. Cancer Chemother Pharmacol 2008;62:647-53. (Pubitemid 352009239)
26. Ito A, Koma Y, Uchino K, Okada T, Ohbayashi C, Tsubota N, et al. Increased expression of connexin 26 in the invasive component of lung squamous cell carcinoma: significant correlation with poor prognosis. Cancer Lett 2006;234:239-48.
27. Naoi Y, Miyoshi Y, Taguchi T, Kim SJ, Arai T, Tamaki Y, et al. Connexin26 expression is associated with lymphatic vessel invasion and poor prognosis in human breast cancer. Breast Cancer Res Treat 2007;106:11-7. (Pubitemid 47498083)
28. Sulkowski S, Kanczuga-Koda L, Koda M, Wincewicz A, Sulkowska M. Insulin-like growth factor-I receptor correlates with connexin 26 and Bcl-xL expression in human colorectal cancer. Ann N Y Acad Sci 2006;1090:265-75. (Pubitemid 47092131)
29. Ito A, Katoh F, Kataoka TR, Okada M, Tsubota N, Asada H, et al. A role for heterologous gap junctions between melanoma and endothelial cells in metastasis. J Clin Invest 2000;105:1189-97. (Pubitemid 30266071)
30. Cottin S, Ghani K, Caruso M. Bystander effect in glioblastoma cells with a predominant cytoplasmic localization of connexin43. Cancer Gene Ther 2008;15:823-31.
31. Yum SW, Zhang J, Valiunas V, Kanaporis G, Brink PR, White TW, et al. Human connexin26 and connexin30 form functional heteromeric and heterotypic channels. Am J Physiol Cell Physiol 2007;293:C1032-48.
32. Zhao HB. Connexin26 is responsible for anionic molecule permeability in the cochlea for intercellular signalling and metabolic communications. Eur J Neurosci 2005;21:1859-68.
33. Maeda S, Nakagawa S, Suga M, Yamashita E, Oshima A, Fujiyoshi Y, et al. Structure of the connexin 26 gap junction channel at 3.5 A resolution. Nature 2009;458:597-602.
34. Nakagawa S, Maeda S, Tsukihara T. Structural and functional studies of gap junction channels. Curr Opin Struct Biol 2010;20:423-30.
35. Goldberg GS, Moreno AP, Lampe PD. Gap junctions between cells expressing connexin 43 or 32 show inverse permselectivity to adenosine and ATP. J Biol Chem 2002;277:36725-30.
36. Ammerpohl O, Trauzold A, Schniewind B, Griep U, Pilarsky C, Grutzmann R, et al. Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br J Cancer 2007;96:73-81. (Pubitemid 46094642)
37. Tomao S, Romiti A, Massidda B, Ionta MT, Farris A, Zullo A, et al. A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer. Anticancer Res 2002;22:2361-4. (Pubitemid 34857066)